{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:28:44Z","timestamp":1778941724496,"version":"3.51.4"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,11,4]],"date-time":"2017-11-04T00:00:00Z","timestamp":1509753600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bundesministerium f\u00fcr Bildung und Forschung (DE)","award":["031A424"],"award-info":[{"award-number":["031A424"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00432-017-2540-1","type":"journal-article","created":{"date-parts":[[2017,11,4]],"date-time":"2017-11-04T16:17:51Z","timestamp":1509812271000},"page":"343-358","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Model-based optimization of G-CSF treatment during cytotoxic chemotherapy"],"prefix":"10.1007","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5497-2791","authenticated-orcid":false,"given":"Sibylle","family":"Schirm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Engel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibylle","family":"Loibl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Loeffler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4059-1779","authenticated-orcid":false,"given":"Markus","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,4]]},"reference":[{"issue":"3","key":"2540_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3747\/co.20.1306","volume":"20","author":"AK Altwairgi","year":"2013","unstructured":"Altwairgi AK, Hopman WM, Mates M (2013) Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia. Curr Oncol 20(3):9. https:\/\/doi.org\/10.3747\/co.20.1306","journal-title":"Curr Oncol"},{"issue":"7","key":"2540_CR2","first-page":"1952","volume":"47","author":"CL Bennett","year":"1987","unstructured":"Bennett CL, Sinkule JA, Schilsky RL, Senekjian E, Choi KE (1987) Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer. Cancer Res 47(7):1952\u20131956","journal-title":"Cancer Res"},{"issue":"12","key":"2540_CR3","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1056\/NEJMct1210890","volume":"368","author":"CL Bennett","year":"2013","unstructured":"Bennett CL, Djulbegovic B, Norris LB, Armitage JO (2013) Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med 368(12):1131\u20131139. https:\/\/doi.org\/10.1056\/NEJMct1210890","journal-title":"N Engl J Med"},{"issue":"13","key":"2540_CR4","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1200\/Jco.2003.06.137","volume":"21","author":"DW Blayney","year":"2003","unstructured":"Blayney DW, LeBlanc ML, Grogan T, Gaynor ER, Chapman RA, Spiridonidis CH, Taylor SA, Bearman SI, Miller TP, Fisher RI (2003) Dose-intense chemotherapy every 2\u00a0weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: A phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol 21(13):2466\u20132473. https:\/\/doi.org\/10.1200\/Jco.2003.06.137","journal-title":"J Clin Oncol"},{"issue":"2","key":"2540_CR5","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1634\/theoncologist.10-2-138","volume":"10","author":"DW Blayney","year":"2005","unstructured":"Blayney DW, McGuire BW, Cruickshank SE, Johnson DH (2005) Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin\u2019s lymphoma. Oncologist 10(2):138\u2013149. https:\/\/doi.org\/10.1634\/theoncologist.10-2-138","journal-title":"Oncologist"},{"key":"2540_CR6","doi-asserted-by":"publisher","unstructured":"Bohlius J, Herbst C, Reiser M, Schwarzer G, Engert A (2008) Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev (4):CD003189. 10.1002\/14651858.CD003189.pub4","DOI":"10.1002\/14651858.CD003189.pub4"},{"issue":"24 Suppl 2","key":"2540_CR7","first-page":"9","volume":"54","author":"R Bruno","year":"1997","unstructured":"Bruno R, Riva A, Hille D, Lebecq A, Thomas L (1997) Pharmacokinetic and pharmacodynamic properties of docetaxel: results of phase I and phase II trials. Am J Health Syst Pharm Off J Am Soc Health Syst Pharm 54(24 Suppl 2):9","journal-title":"Am J Health Syst Pharm Off J Am Soc Health Syst Pharm"},{"issue":"9","key":"2540_CR8","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1182\/blood.V84.9.2923.2923","volume":"84","author":"GS Chatta","year":"1994","unstructured":"Chatta GS, Price TH, Allen RC, Dale DC (1994) Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood 84(9):2923\u20132929","journal-title":"Blood"},{"issue":"8","key":"2540_CR9","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1097\/CAD.0000000000000115","volume":"25","author":"C Cheng","year":"2014","unstructured":"Cheng C, Gallagher EM, Yeh J-Y, Earl MA (2014) Rates of febrile neutropenia with pegfilgrastim on same day versus next day of CHOP with or without rituximab. Anticancer Drugs 25(8):964\u2013969. https:\/\/doi.org\/10.1097\/CAD.0000000000000115","journal-title":"Anticancer Drugs"},{"issue":"1","key":"2540_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/HP.0b013e3182a4df10","volume":"106","author":"HL Chua","year":"2014","unstructured":"Chua HL, Plett PA, Sampson CH, Katz BP, Carnathan GW, MacVittie TJ, Lenden K, Orschell CM (2014) Survival efficacy of the PEGylated G-CSFs Maxy-G34 and neulasta in a mouse model of lethal H-ARS, and residual bone marrow damage in treated survivors. Health Phys 106(1):21\u201338. https:\/\/doi.org\/10.1097\/HP.0b013e3182a4df10","journal-title":"Health Phys"},{"key":"2540_CR11","doi-asserted-by":"publisher","unstructured":"Clark OAC, Lyman G, Castro AA, Clark LGO, Djulbegovic B (2003) Colony stimulating factors for chemotherapy induced febrile neutropenia. Cochrane Database Syst Rev (3):CD003039. 10.1002\/14651858.CD003039","DOI":"10.1002\/14651858.CD003039"},{"issue":"18","key":"2540_CR12","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1200\/JCO.2005.05.645","volume":"23","author":"OAC Clark","year":"2005","unstructured":"Clark OAC, Lyman GH, Castro AA, Clark LGO, Djulbegovic B (2005) Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 23(18):4198\u20134214. https:\/\/doi.org\/10.1200\/JCO.2005.05.645","journal-title":"J Clin Oncol"},{"issue":"8","key":"2540_CR13","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1182\/blood.V80.8.2012.2012","volume":"80","author":"F Colotta","year":"1992","unstructured":"Colotta F, Re F, Polentarutti N, Sozzani S, Mantovani A (1992) Modulation of granulocyte survival and programmed cell-death by cytokines and bacterial products. Blood 80(8):2012\u20132020","journal-title":"Blood"},{"key":"2540_CR14","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/1471-2407-11-404","volume":"11","author":"KL Cooper","year":"2011","unstructured":"Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 11:404. https:\/\/doi.org\/10.1186\/1471-2407-11-404","journal-title":"BMC Cancer"},{"key":"2540_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jtbi.2015.08.015","volume":"385","author":"M Craig","year":"2015","unstructured":"Craig M, Humphries AR, Nekka F, Belair J, Li J, Mackey MC (2015) Neutrophil dynamics during concurrent chemotherapy and G-CSF administration: mathematical modelling guides dose optimisation to minimise neutropenia. J Theor Biol 385:77\u201389. https:\/\/doi.org\/10.1016\/j.jtbi.2015.08.015","journal-title":"J Theor Biol"},{"issue":"3","key":"2540_CR16","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/NEJM199107183250305","volume":"325","author":"J Crawford","year":"1991","unstructured":"Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325(3):164\u2013170. https:\/\/doi.org\/10.1056\/NEJM199107183250305","journal-title":"N Engl J Med"},{"issue":"11","key":"2540_CR17","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1023\/A:1008271804151","volume":"8","author":"J Crawford","year":"1997","unstructured":"Crawford J, Kreisman H, Garewal H, Jones SE, Shoemaker D, Pupa MR, Armstrong S, Tomita D, Dziem G (1997) The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy. Ann Oncol 8(11):1117\u20131124","journal-title":"Ann Oncol"},{"issue":"2","key":"2540_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cncr.11882","volume":"100","author":"J Crawford","year":"2004","unstructured":"Crawford J, Dale DC, Lyman GH (2004) Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100(2):228\u2013237. https:\/\/doi.org\/10.1002\/cncr.11882","journal-title":"Cancer"},{"issue":"Suppl 1","key":"2540_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-200262001-00001","volume":"62","author":"DC Dale","year":"2002","unstructured":"Dale DC (2002) Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs 62(Suppl 1):1\u201315","journal-title":"Drugs"},{"issue":"4 Suppl 13","key":"2540_CR20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0093-7754(03)00326-9","volume":"30","author":"D Dale","year":"2003","unstructured":"Dale D (2003) Current management of chemotherapy-induced neutropenia: the role of colony-stimulating factors. Semin Oncol 30(4 Suppl 13):3\u20139","journal-title":"Semin Oncol"},{"issue":"2","key":"2540_CR21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/030089160909500214","volume":"95","author":"M Danova","year":"2009","unstructured":"Danova M, Chiroli S, Rosti G, Doan QV (2009) Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients. Tumori 95(2):219\u2013226","journal-title":"Tumori"},{"issue":"24","key":"2540_CR22","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/Nejmoa022473","volume":"348","author":"V Diehl","year":"2003","unstructured":"Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, Tesch H, Herrmann R, Dorken B, Muller-Hermelink H, Duhmke E, Loeffler M, German Hodgkin\u2019s Lymphoma Study Group [Nachname nicht vorhanden] (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin\u2019s disease. N Engl J Med 348(24):2386\u20132395. https:\/\/doi.org\/10.1056\/Nejmoa022473","journal-title":"N Engl J Med"},{"issue":"3","key":"2540_CR23","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1056\/NEJMc1306109","volume":"369","author":"B Djulbegovic","year":"2013","unstructured":"Djulbegovic B, Norris LB, Bennett CL (2013) Colony-stimulating factors for febrile neutropenia. N Engl J Med 369(3):286. https:\/\/doi.org\/10.1056\/NEJMc1306109","journal-title":"N Engl J Med"},{"issue":"8","key":"2540_CR24","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1182\/blood-2004-01-0306","volume":"104","author":"C Engel","year":"2004","unstructured":"Engel C, Scholz M, Loeffler M (2004) A computational model of human granulopoiesis to simulate the hematotoxic effects of multicycle polychemotherapy. Blood 104(8):2323\u20132331. https:\/\/doi.org\/10.1182\/blood-2004-01-0306","journal-title":"Blood"},{"issue":"6","key":"2540_CR25","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/j.1600-0609.2006.00741.x","volume":"77","author":"E Faber","year":"2006","unstructured":"Faber E, Pytlik R, Slaby J, Zapletalova J, Kozak T, Raida L, Papajik T, Zikesova E, Maresova I, Hamouzova M, Indrak K, Trneny M (2006) Individually determined dosing of filgrastim after autologous peripheral stem cell transplantation in patients with malignant lymphoma\u2014results of a prospective multicentre controlled trial. Eur J Haematol 77(6):493\u2013500. https:\/\/doi.org\/10.1111\/j.1600-0609.2006.00741.x","journal-title":"Eur J Haematol"},{"issue":"1","key":"2540_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1586\/17474086.2015.983470","volume":"8","author":"A Georgala","year":"2015","unstructured":"Georgala A, Klastersky JA (2015) Prophylaxis of febrile neutropenia in adults receiving chemotherapy needs to be adapted to the risk. Expert Rev Hematol 8(1):115\u2013121. https:\/\/doi.org\/10.1586\/17474086.2015.983470","journal-title":"Expert Rev Hematol"},{"issue":"219","key":"2540_CR27","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/1471-2105-15-219","volume":"15","author":"A Gross","year":"2014","unstructured":"Gross A, Schirm S, Scholz M (2014) Ycasd\u2014a tool for capturing and scaling data from graphical representations. BMC Bioinform 15(219):219. https:\/\/doi.org\/10.1186\/1471-2105-15-219","journal-title":"BMC Bioinform"},{"issue":"3","key":"2540_CR28","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nrd1033","volume":"2","author":"JM Harris","year":"2003","unstructured":"Harris JM, Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2(3):214\u2013221. https:\/\/doi.org\/10.1038\/nrd1033","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"2540_CR29","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/annonc\/mdf130","volume":"13","author":"FA Holmes","year":"2002","unstructured":"Holmes FA, Jones SE, O\u2019Shaughnessy J, Vukelja S, George T, Savin M, Richards D, Glaspy J, Meza L, Cohen G, Dhami M, Budman DR, Hackett J, Brassard M, Yang BB, Liang BC (2002) Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol Off J Eur Soc Med Oncol 13(6):903\u2013909","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"3","key":"2540_CR30","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1046\/j.1365-2125.1999.00888.x","volume":"47","author":"AC Houston","year":"1999","unstructured":"Houston AC, Stevens LA, Cour V (1999) Pharmacokinetics of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) in healthy male volunteers. Brit J Clin Pharmacol 47(3):279\u2013284","journal-title":"Brit J Clin Pharmacol"},{"issue":"5","key":"2540_CR31","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/annonc\/mdn051","volume":"19","author":"H Ishiguro","year":"2008","unstructured":"Ishiguro H, Kitano T, Yoshibayashi H, Toi M, Ueno T, Yasuda H, Yanagihara K, Garbo CL, Fukushima M (2008) Prolonged neutropenia after dose-dense chemotherapy with pegfilgrastim. Ann Oncol 19(5):1019. https:\/\/doi.org\/10.1093\/annonc\/mdn051 (author reply 1019\u201320)","journal-title":"Ann Oncol"},{"issue":"7","key":"2540_CR32","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3109\/07357909909032859","volume":"17","author":"L Iyer","year":"1999","unstructured":"Iyer L, Ratain MJ (1999) 5-Fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy. Cancer Investig 17(7):494\u2013506","journal-title":"Cancer Investig"},{"issue":"18","key":"2540_CR33","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1158\/1078-0432.CCR-06-0815","volume":"12","author":"C Kloft","year":"2006","unstructured":"Kloft C, Wallin J, Henningsson A, Chatelut E, Karlsson MO (2006) Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clin Cancer Res Off J Am Assoc Cancer Res 12(18):5481\u20135490. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0815","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"4","key":"2540_CR34","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00520-014-2597-1","volume":"23","author":"Y Kosaka","year":"2015","unstructured":"Kosaka Y, Rai Y, Masuda N, Takano T, Saeki T, Nakamura S, Shimazaki R, Ito Y, Tokuda Y, Tamura K (2015) Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel\/cyclophosphamide chemotherapy. Support Care Cancer 23(4):1137\u20131143. https:\/\/doi.org\/10.1007\/s00520-014-2597-1","journal-title":"Support Care Cancer"},{"key":"2540_CR35","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1124\/dmd.107.015669","volume":"35","author":"J Kota","year":"2007","unstructured":"Kota J, Machavaram KK, McLennan DN, Edwards GA, Porter CJ, Charman SA (2007) Lymphatic absorption of subcutaneously administered proteins: influence of different injection sites on the absorption of darbepoetin alfa using a sheep model. Drug Metab Dispos 35:2211\u20132217","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"2540_CR36","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10):2258\u20132266. https:\/\/doi.org\/10.1002\/cncr.21847","journal-title":"Cancer"},{"issue":"21","key":"2540_CR37","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1200\/Jco.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25(21):3158\u20133167. https:\/\/doi.org\/10.1200\/Jco.2006.08.8823","journal-title":"J Clin Oncol"},{"issue":"3","key":"2540_CR38","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0022-3565(25)23988-X","volume":"271","author":"T Kuwabara","year":"1994","unstructured":"Kuwabara T, Kato Y, Kobayashi S, Suzuki H, Sugiyama Y (1994) Nonlinear pharmacokinetics of a recombinant human granulocyte-colony-stimulating factor derivative (nartograstim)\u2014species-differences among rats, monkeys and humans. J Pharmacol Exp Ther 271(3):1535\u20131543","journal-title":"J Pharmacol Exp Ther"},{"issue":"1 Pt 1","key":"2540_CR39","first-page":"84","volume":"271","author":"T Kuwabara","year":"1996","unstructured":"Kuwabara T, Kobayashi S, Sugiyama Y (1996a) Kinetic analysis of receptor-mediated endocytosis of G-CSF derivative, nartograstim, in rat bone marrow cells. Am J Physiol 271(1 Pt 1):84","journal-title":"Am J Physiol"},{"issue":"4","key":"2540_CR40","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3109\/03602539608994020","volume":"28","author":"T Kuwabara","year":"1996","unstructured":"Kuwabara T, Kobayashi S, Sugiyama Y (1996b) Pharmacokinetics and pharmacodynamics of a recombinant human granulocyte colony-stimulating factor. Drug Metab Rev 28(4):625\u2013658. https:\/\/doi.org\/10.3109\/03602539608994020","journal-title":"Drug Metab Rev"},{"issue":"12","key":"2540_CR41","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1517\/14712598.2015.1101063","volume":"15","author":"M Lambertini","year":"2015","unstructured":"Lambertini M, Ferreira AR, Del Mastro L, Danesi R, Pronzato P (2015) Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors. Expert Opin Biol Ther 15(12):1799\u20131817. https:\/\/doi.org\/10.1517\/14712598.2015.1101063","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"2540_CR42","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00520-012-1589-2","volume":"21","author":"S Lee","year":"2013","unstructured":"Lee S, Knox A, Zeng ISL, Coomarasamy C, Blacklock H, Issa S (2013) Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis. Support Care Cancer 21(3):841\u2013846. https:\/\/doi.org\/10.1007\/s00520-012-1589-2","journal-title":"Support Care Cancer"},{"issue":"12","key":"2540_CR43","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1093\/annonc\/mdv389","volume":"26","author":"RCF Leonard","year":"2015","unstructured":"Leonard RCF, Mansi JL, Keerie C, Yellowlees A, Crawford S, Benstead K, Matthew R, Adamson D, Chan S, Grieve R (2015) A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor (\u2018SPROG\u2019 trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRN. Ann Oncol 26(12):2437\u20132441. https:\/\/doi.org\/10.1093\/annonc\/mdv389","journal-title":"Ann Oncol"},{"key":"2540_CR44","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3277-0","author":"Y Li","year":"2016","unstructured":"Li Y, Klippel Z, Shih X, Reiner M, Wang H, Page JH (2016) Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies. Support Care Cancer. https:\/\/doi.org\/10.1007\/s00520-016-3277-0","journal-title":"Support Care Cancer"},{"issue":"11","key":"2540_CR45","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1007\/s00520-010-1020-9","volume":"19","author":"S Loibl","year":"2011","unstructured":"Loibl S, Mueller V, von Minckwitz G, Conrad B, Koehne C-H, Kremers S, Forstbauer H, Linder M, Nekljudova V, Moebus V (2011) Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33). Support Care Cancer 19(11):1789\u20131795. https:\/\/doi.org\/10.1007\/s00520-010-1020-9","journal-title":"Support Care Cancer"},{"issue":"23","key":"2540_CR46","doi-asserted-by":"crossref","first-page":"9499","DOI":"10.1073\/pnas.86.23.9499","volume":"86","author":"BI Lord","year":"1989","unstructured":"Lord BI, Bronchud MH, Owens S, Chang J, Howell A, Souza L, Dexter TM (1989) The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proc Natl Acad Sci USA 86(23):9499\u20139503","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2540_CR47","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1185\/03007990802636817","volume":"25","author":"G Lyman","year":"2009","unstructured":"Lyman G, Lalla A, Barron R, Dubois RW (2009) Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin\u2019s lymphoma receiving CHOP-21 in United States. Curr Med Res Opin 25(2):401\u2013411. https:\/\/doi.org\/10.1185\/03007990802636817","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"2540_CR48","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1365-2184.2003.00251.x","volume":"36","author":"MC Mackey","year":"2003","unstructured":"Mackey MC, Aprikyan AA, Dale DC (2003) The rate of apoptosis in post mitotic neutrophil precursors of normal and neutropenic humans. Cell Prolif 36(1):27\u201334","journal-title":"Cell Prolif"},{"issue":"10","key":"2540_CR49","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1007\/s00520-015-2654-4","volume":"23","author":"N Masuda","year":"2015","unstructured":"Masuda N, Tokuda Y, Nakamura S, Shimazaki R, Ito Y, Tamura K (2015) Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial. Support Care Cancer 23(10):2891\u20132898. https:\/\/doi.org\/10.1007\/s00520-015-2654-4","journal-title":"Support Care Cancer"},{"key":"2540_CR50","doi-asserted-by":"publisher","unstructured":"Mhaskar R, Clark OAC, Lyman G, Engel Ayer Botrel T, Morganti Paladini L, Djulbegovic B (2014) Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev (10):CD003039. 10.1002\/14651858.CD003039.pub2","DOI":"10.1002\/14651858.CD003039.pub2"},{"issue":"17","key":"2540_CR51","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1200\/JCO.2009.24.7643","volume":"28","author":"V Moebus","year":"2010","unstructured":"Moebus V, Jackisch C, Lueck H-J, Du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Schneeweiss A, Huober J, Harbeck N, von Minckwitz G, Runnebaum IB, Hinke A, Kreienberg R, Konecny GE, Untch M (2010) Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 28(17):2874\u20132880. https:\/\/doi.org\/10.1200\/JCO.2009.24.7643","journal-title":"J Clin Oncol"},{"issue":"Suppl A","key":"2540_CR52","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0305-7372(02)80004-4","volume":"28","author":"G Molineux","year":"2002","unstructured":"Molineux G (2002) Pegylation: engineering improved pharmaceuticals for enhanced therapy. Cancer Treat Rev 28(Suppl A):13\u201316","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"2540_CR53","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/s11095-014-1493-1","volume":"32","author":"ML Pastor","year":"2015","unstructured":"Pastor ML, Laffont CM, Gladieff L, Chatelut E, Concordet D (2015) Model-based approach to early predict prolonged high grade neutropenia in carboplatin-treated patients and guide G-CSF prophylactic treatment. Pharm Res 32(2):654\u2013664. https:\/\/doi.org\/10.1007\/s11095-014-1493-1","journal-title":"Pharm Res"},{"issue":"6","key":"2540_CR54","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood.V80.6.1430.1430","volume":"80","author":"R Pettengell","year":"1992","unstructured":"Pettengell R, Gurney H, Radford JA, Deakin DP, James R, Wilkinson PM, Kane K, Bentley J, Crowther D (1992) Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin\u2019s lymphoma: a randomized controlled trial. Blood 80(6):1430\u20131436","journal-title":"Blood"},{"issue":"3","key":"2540_CR55","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","volume":"104","author":"M Pfreundschuh","year":"2004","unstructured":"Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M (2004a) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104(3):634\u2013641. https:\/\/doi.org\/10.1182\/blood-2003-06-2095","journal-title":"Blood"},{"issue":"3","key":"2540_CR56","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","volume":"104","author":"M Pfreundschuh","year":"2004","unstructured":"Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, Schmitz N, Glass B, Rube C, Loeffler M (2004b) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 104(3):626\u2013633. https:\/\/doi.org\/10.1182\/blood-2003-06-2094","journal-title":"Blood"},{"issue":"2","key":"2540_CR57","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trumper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M, German High-Grade Non-Hodgkin Lymphoma Study Group (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20\u00a0+\u00a0B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9(2):105\u2013116. https:\/\/doi.org\/10.1016\/S1470-2045(08)70002-0","journal-title":"Lancet Oncol"},{"issue":"12","key":"2540_CR58","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1007\/s11095-014-1429-9","volume":"31","author":"AL Quartino","year":"2014","unstructured":"Quartino AL, Karlsson MO, Lindman H, Friberg LE (2014) Characterization of endogenous G-CSF and the inverse correlation to chemotherapy-induced neutropenia in patients with breast cancer using population modeling. Pharm Res 31(12):3390\u20133403. https:\/\/doi.org\/10.1007\/s11095-014-1429-9","journal-title":"Pharm Res"},{"key":"2540_CR59","volume-title":"Evolutionsstrategie","author":"I Rechenberg","year":"1973","unstructured":"Rechenberg I (1973) Evolutionsstrategie. Optimierung technischer Systeme nach Prinzipien der biologischen Evolution. Frommann-Holzboog, Stuttgart"},{"key":"2540_CR60","volume-title":"Evolutionsstrategie 94","author":"I Rechenberg","year":"1994","unstructured":"Rechenberg I (1994) Evolutionsstrategie 94. Frommann-Holzboog, Stuttgart"},{"issue":"2","key":"2540_CR61","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s11538-013-9925-3","volume":"76","author":"K Roesch","year":"2014","unstructured":"Roesch K, Hasenclever D, Scholz M (2014) Modelling lymphoma therapy and outcome. Bull Math Biol 76(2):401\u2013430. https:\/\/doi.org\/10.1007\/s11538-013-9925-3","journal-title":"Bull Math Biol"},{"issue":"7","key":"2540_CR62","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.3109\/10428194.2015.1110746","volume":"57","author":"K Rosch","year":"2016","unstructured":"Rosch K, Scholz M, Hasenclever D (2016) Modeling combined chemo- and immunotherapy of high-grade non-Hodgkin lymphoma. Leuk Lymphoma 57(7):1697\u20131708. https:\/\/doi.org\/10.3109\/10428194.2015.1110746","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2540_CR63","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/1097-0142(19940801)74:3<834::AID-CNCR2820740308>3.0.CO;2-9","volume":"74","author":"DA Rushing","year":"1994","unstructured":"Rushing DA, Raber SR, Rodvold KA, Piscitelli SC, Plank GS, Tewksbury DA (1994) The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer 74(3):834\u2013841","journal-title":"Cancer"},{"issue":"3","key":"2540_CR64","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1021\/bp020017g","volume":"19","author":"CA Sarkar","year":"2003","unstructured":"Sarkar CA, Lowenhaupt K, Wang PJ, Horan T, Lauffenburger DA (2003) Parsing the effects of binding, signaling, and trafficking on the mitogenic potencies of granulocyte colony-stimulating factor analogues. Biotechnol Prog 19(3):955\u2013964. https:\/\/doi.org\/10.1021\/bp020017g","journal-title":"Biotechnol Prog"},{"issue":"6","key":"2540_CR65","doi-asserted-by":"publisher","first-page":"e65630","DOI":"10.1371\/journal.pone.0065630","volume":"8","author":"S Schirm","year":"2013","unstructured":"Schirm S, Engel C, Loeffler M, Scholz M (2013) A biomathematical model of human erythropoiesis under erythropoietin and chemotherapy administration. PLoS One 8(6):e65630. https:\/\/doi.org\/10.1371\/journal.pone.0065630","journal-title":"PLoS One"},{"key":"2540_CR66","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1742-4682-11-24","volume":"11","author":"S Schirm","year":"2014","unstructured":"Schirm S, Engel C, Loeffler M, Scholz M (2014a) A combined model of human erythropoiesis and granulopoiesis under growth factor and chemotherapy treatment. Theor Biol Med Model 11:24. https:\/\/doi.org\/10.1186\/1742-4682-11-24","journal-title":"Theor Biol Med Model"},{"issue":"1","key":"2540_CR67","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12918-014-0138-7","volume":"8","author":"S Schirm","year":"2014","unstructured":"Schirm S, Engel C, Loeffler M, Scholz M (2014b) Modelling chemotherapy effects on granulopoiesis. BMC Syst Biol 8(1):5. https:\/\/doi.org\/10.1186\/s12918-014-0138-7","journal-title":"BMC Syst Biol"},{"issue":"6","key":"2540_CR68","first-page":"755","volume":"21","author":"S Schmitz","year":"1993","unstructured":"Schmitz S, Franke H, Brusis J, Wichmann HE (1993) Quantification of the cell kinetic effects of G-CSF using a model of human granulopoiesis. Exp Hematol 21(6):755\u2013760","journal-title":"Exp Hematol"},{"issue":"4","key":"2540_CR69","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00285-004-0295-1","volume":"50","author":"M Scholz","year":"2005","unstructured":"Scholz M, Engel C, Loeffler M (2005) Modelling human granulopoiesis under poly-chemotherapy with G-CSF support. J Math Biol 50(4):397\u2013439. https:\/\/doi.org\/10.1007\/s00285-004-0295-1","journal-title":"J Math Biol"},{"issue":"6","key":"2540_CR70","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/j.1365-2141.2005.05957.x","volume":"132","author":"M Scholz","year":"2006","unstructured":"Scholz M, Engel C, Loeffler M, German High Grade Non-Hodgkin Lymphoma Study Group (2006) Model-based design of chemotherapeutic regimens that account for heterogeneity in leucopoenia. Br J Haematol 132(6):723\u2013735. https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05957.x","journal-title":"Br J Haematol"},{"issue":"6","key":"2540_CR71","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1111\/j.1365-2184.2009.00638.x","volume":"42","author":"M Scholz","year":"2009","unstructured":"Scholz M, Ackermann M, Engel C, Emmrich F, Loeffler M, Kamprad M (2009a) A pharmacokinetic model of filgrastim and pegfilgrastim application in normal mice and those with cyclophosphamide-induced granulocytopaenia. Cell Prolif 42(6):813\u2013822. https:\/\/doi.org\/10.1111\/j.1365-2184.2009.00638.x","journal-title":"Cell Prolif"},{"issue":"6","key":"2540_CR72","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/j.1365-2184.2009.00641.x","volume":"42","author":"M Scholz","year":"2009","unstructured":"Scholz M, Engel C, Apt D, Sankar SL, Goldstein E, Loeffler M (2009b) Pharmacokinetic and pharmacodynamic modelling of the novel human granulocyte colony-stimulating factor derivative Maxy-G34 and pegfilgrastim in rats. Cell Prolif 42(6):823\u2013837. https:\/\/doi.org\/10.1111\/j.1365-2184.2009.00641.x","journal-title":"Cell Prolif"},{"key":"2540_CR73","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1742-4682-9-32","volume":"9","author":"M Scholz","year":"2012","unstructured":"Scholz M, Schirm S, Wetzler M, Engel C, Loeffler M (2012) Pharmacokinetic and -dynamic modelling of G-CSF derivatives in humans. Theor Biol Med Model 9:32. https:\/\/doi.org\/10.1186\/1742-4682-9-32","journal-title":"Theor Biol Med Model"},{"issue":"9","key":"2540_CR74","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1200\/Jco.2003.06.028","volume":"21","author":"M Sieber","year":"2003","unstructured":"Sieber M, Bredenfeld H, Josting A, Reineke T, Rueffer U, Koch T, Naumann R, Boissevain F, Koch P, Worst P, Soekler M, Eich H, Muller-Hermelink HK, Franklin J, Paulus U, Wolf J, Engert A, Diehl V (2003) 14-Day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin\u2019s lymphoma: results of a pilot study of the German Hodgkin\u2019s Lymphoma Study Group. J Clin Oncol 21(9):1734\u20131739. https:\/\/doi.org\/10.1200\/Jco.2003.06.028","journal-title":"J Clin Oncol"},{"issue":"3","key":"2540_CR75","first-page":"229","volume":"71","author":"A Sulkes","year":"1987","unstructured":"Sulkes A, Collins JM (1987) Reappraisal of some dosage adjustment guidelines. Cancer Treat Rep 71(3):229\u2013233","journal-title":"Cancer Treat Rep"},{"issue":"6","key":"2540_CR76","doi-asserted-by":"crossref","first-page":"400","DOI":"10.7326\/0003-4819-147-6-200709180-00010","volume":"147","author":"L Sung","year":"2007","unstructured":"Sung L, Nathan PC, Alibhai SMH, Tomlinson GA, Beyene J (2007) Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 147(6):400\u2013411","journal-title":"Ann Intern Med"},{"issue":"3","key":"2540_CR77","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/annonc\/mdm497","volume":"19","author":"L Trumper","year":"2008","unstructured":"Trumper L, Zwick C, Ziepert M, Hohloch K, Schmits R, Mohren M, Liersch R, Bentz M, Graeven U, Wruck U, Hoffmann M, Metzner B, Hasenclever D, Loeffler M, Pfreundschuh M, German High-Grade Non-Hodgkin\u2019s Lymphoma Study Group (2008) Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin\u2019s lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens. Ann Oncol Off J Eur Soc Med Oncol 19(3):538\u2013544. https:\/\/doi.org\/10.1093\/annonc\/mdm497","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"9","key":"2540_CR78","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1093\/annonc\/mdq709","volume":"22","author":"M Untch","year":"2011","unstructured":"Untch M, Fasching PA, Konecny GE, von Koch F, Conrad U, Fett W, Kurzeder C, Luck HJ, Stickeler E, Urbaczyk H, Liedtke B, Salat C, Harbeck N, Muller V, Schmidt M, Hasmuller S, Lenhard M, Schuster T, Nekljudova V, Lebeau A, Loibl S, von Minckwitz G, Arbeitsgemeinschaft Gynakologische Onkologie Prepare Investigators (2011a) PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin\/cyclophosphamide followed by paclitaxel\u00a0\u00b1\u00a0darbepoetin alfa in primary breast cancer\u2014results at the time of surgery. Ann Oncol Off J Eur Soc Med Oncol 22(9):1988\u20131998. https:\/\/doi.org\/10.1093\/annonc\/mdq709","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"9","key":"2540_CR79","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1093\/annonc\/mdq713","volume":"22","author":"M Untch","year":"2011","unstructured":"Untch M, von Minckwitz G, Konecny GE, Conrad U, Fett W, Kurzeder C, Luck HJ, Stickeler E, Urbaczyk H, Liedtke B, Beckmann MW, Salat C, Harbeck N, Muller V, Schmidt M, Hasmuller S, Lenhard M, Nekljudova V, Lebeau A, Loibl S, Fasching PA, Arbeitsgemeinschaft Gynakologische Onkologie Prepare Investigators (2011b) PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer\u2014outcome on prognosis. Ann Oncol Off J Eur Soc Med Oncol 22(9):1999\u20132006. https:\/\/doi.org\/10.1093\/annonc\/mdq713","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"5","key":"2540_CR80","first-page":"315","volume":"22","author":"FM Veronese","year":"2008","unstructured":"Veronese FM, Mero A (2008) The impact of PEGylation on biological therapies. BioDrugs Clin Immunother Biopharm Gene Ther 22(5):315\u2013329","journal-title":"BioDrugs Clin Immunother Biopharm Gene Ther"},{"issue":"6","key":"2540_CR81","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","volume":"23","author":"CL Vogel","year":"2005","unstructured":"Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, Neumann TA, Schwartzberg LS (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23(6):1178\u20131184. https:\/\/doi.org\/10.1200\/JCO.2005.09.102","journal-title":"J Clin Oncol"},{"issue":"3","key":"2540_CR82","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1200\/JCO.2003.03.040","volume":"21","author":"JM Vose","year":"2003","unstructured":"Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J, Frankel S, Flinn I, Lovelace W, Hackett J, Liang BC (2003) Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 21(3):514\u2013519","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"2540_CR83","doi-asserted-by":"publisher","first-page":"e0148901","DOI":"10.1371\/journal.pone.0148901","volume":"11","author":"XJ Wang","year":"2016","unstructured":"Wang XJ, Tang T, Farid M, Quek R, Tao M, Lim ST, Wee HL, Chan A (2016) Routine primary prophylaxis for febrile neutropenia with biosimilar granulocyte colony-stimulating factor (nivestim) or pegfilgrastim is cost effective in non-hodgkin lymphoma patients undergoing curative-intent R-CHOP chemotherapy. PLoS One 11(2):e0148901. https:\/\/doi.org\/10.1371\/journal.pone.0148901","journal-title":"PLoS One"},{"issue":"3","key":"2540_CR84","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.ygyno.2008.10.025","volume":"112","author":"JM Whitworth","year":"2009","unstructured":"Whitworth JM, Matthews KS, Shipman KA, Numnum TM, Kendrick JE, Kilgore LC, Straughn JM Jr (2009) The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies. Gynecol Oncol 112(3):601\u2013604. https:\/\/doi.org\/10.1016\/j.ygyno.2008.10.025","journal-title":"Gynecol Oncol"},{"issue":"5","key":"2540_CR85","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1002\/Jps.20024","volume":"93","author":"BB Yang","year":"2004","unstructured":"Yang BB, Lum PK, Hayashi MM, Roskos LK (2004) Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats. J Pharm Sci 93(5):1367\u20131373. https:\/\/doi.org\/10.1002\/Jps.20024","journal-title":"J Pharm Sci"},{"issue":"Suppl 2","key":"2540_CR86","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/annonc\/5.suppl_2.S127","volume":"5","author":"V Zagonel","year":"1994","unstructured":"Zagonel V, Babare R, Merola MC, Talamini R, Lazzarini R, Tirelli U, Carbone A, Monfardini S (1994) Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin\u2019s lymphoma treated with combination chemotherapy. Ann Oncol 5(Suppl 2):127\u2013132","journal-title":"Ann Oncol"},{"issue":"8 Pt 2","key":"2540_CR87","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1592\/phco.23.9.9S.32888","volume":"23","author":"WC Zamboni","year":"2003","unstructured":"Zamboni WC (2003) Pharmacokinetics of pegfilgrastim. Pharmacotherapy 23(8 Pt 2):9\u201314","journal-title":"Pharmacotherapy"},{"issue":"12","key":"2540_CR88","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1007\/s00277-013-1842-x","volume":"92","author":"S Zeynalova","year":"2013","unstructured":"Zeynalova S, Ziepert M, Scholz M, Schirm S, Zwick C, Pfreundschuh M, Loeffler M, German High-Grade Non-Hodgkin Lymphoma Study Group (2013) Comparison and modelling of pegylated or unpegylated G-CSF schedules in CHOP-14 regimen of elderly patients with aggressive B-cell lymphoma. Ann Hematol 92(12):1641\u20131652. https:\/\/doi.org\/10.1007\/s00277-013-1842-x","journal-title":"Ann Hematol"},{"issue":"4","key":"2540_CR89","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1093\/annonc\/mdm541","volume":"19","author":"M Ziepert","year":"2008","unstructured":"Ziepert M, Schmits R, Trumper L, Pfreundschuh M, Loeffler M, German High-Grade Non-Hodgkin\u2019s Lymphoma Study Group (2008) Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin\u2019s lymphoma. Ann Oncol Off J Eur Soc Med Oncol 19(4):752\u2013762. https:\/\/doi.org\/10.1093\/annonc\/mdm541","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"8","key":"2540_CR90","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1093\/annonc\/mdq674","volume":"22","author":"C Zwick","year":"2011","unstructured":"Zwick C, Hartmann F, Zeynalova S, Poschel V, Nickenig C, Reiser M, Lengfelder E, Peter N, Schlimok G, Schubert J, Schmitz N, Loeffler M, Pfreundschuh M, German High-Grade Non-Hodgkin Lymphoma Study Group (2011) Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia. Ann Oncol Off J Eur Soc Med Oncol 22(8):1872\u20131877. https:\/\/doi.org\/10.1093\/annonc\/mdq674","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-017-2540-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2540-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2540-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T21:39:40Z","timestamp":1750973980000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-017-2540-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,4]]},"references-count":90,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["2540"],"URL":"https:\/\/doi.org\/10.1007\/s00432-017-2540-1","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,4]]}}}